SCHEMBL6846396

SCHEMBL6846396

Nc1nc(Sc2cccc(O)c2)c2ncn(CCOCP(=O)(OCC(F)(F)F)OCC(F)(F)F)c2n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC22A6 Q4U2R8 2/20 0.39
POLA1 P09884 2/20 0.39
POLG P54098 2/20 0.39
ABCB11 O95342 1/20 0.39
FAP Q12884 1/20 0.39
POLB P06746 4/20 0.38
FGFR1 P11362 2/20 0.36
CYP2C19 P33261 3/20 0.35
CYP1A2 P05177 3/20 0.33
SLC29A1 Q99808 2/20 0.33
HK1 P19367 1/20 0.33
HKDC1 Q2TB90 1/20 0.33
CYP3A4 P08684 2/20 0.33
CYP2C9 P11712 2/20 0.33
HIF1A Q16665 2/20 0.33
ALDH1A1 P00352 1/20 0.33
PHLPP2 Q6ZVD8 1/20 0.33
PNP P00491 2/20 0.32
CYP2D6 P10635 1/20 0.32
HPRT1 P00492 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6844548 0.91 SLC22A6 (0.41) SLC22A6POLA1POLGABCB11FAP
SCHEMBL15531905 0.90 SLC22A6 (0.40) SLC22A6POLA1POLGABCB11FAP
SCHEMBL6846450 0.87 FGFR1 (0.49) SLC22A6POLA1POLGPOLBFGFR1
SCHEMBL6847969 0.85 SLC22A6 (0.40) SLC22A6POLA1POLGABCB11FAP
SCHEMBL6847667 0.85 FAP (0.40) FAPCYP2C19CYP1A2SLC29A1HK1
Alamifovir SCHEMBL29388338 0.84 SLC22A6 (0.40) SLC22A6POLA1POLGABCB11FAP
Alamifovir SCHEMBL4971117 0.84 SLC22A6 (0.40) SLC22A6POLA1POLGABCB11FAP
SCHEMBL6846489 0.84 POLB (0.46) SLC22A6POLA1POLGABCB11FAP
SCHEMBL6840927 0.83 POLB (0.41) SLC22A6POLA1POLGABCB11FAP
SCHEMBL7127268 0.82 CYP2C19 (0.35) POLBCYP2C19CYP1A2SLC29A1HK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6767900-B2 VIRICIDES AGAINST HERPES, HUMAN IMMUNODEFICIENCY, HEPATITIS, CYTOMEGALO AND VARICELLA- ZOSTER VIRUSES MITSUBISHI PHARMA CORPORATION (JP) 2004-07-27 US claimed
US-20030153534-A1 Phosphonate nucleotide compound MITSUBISHI PHARMA CORPORATION (JP) 2003-08-14 US claimed
US-6767900-B2 VIRICIDES AGAINST HERPES, HUMAN IMMUNODEFICIENCY, HEPATITIS, CYTOMEGALO AND VARICELLA- ZOSTER VIRUSES MITSUBISHI PHARMA CORPORATION (JP) 2004-07-27 US disclosed
US-20030153534-A1 Phosphonate nucleotide compound MITSUBISHI PHARMA CORPORATION (JP) 2003-08-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030153534-A1 Phosphonate nucleotide compound TYMP, PNP, MTAP SLC22A6 451/4885POLA1 277/4885POLG 434/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.